SCHEMBL15210449

SCHEMBL15210449

COc1ccc(C(N)=O)cc1-c1cc2nccc(-c3cc4[nH]cnc4cc3OC)c2o1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 1/20 0.41
POLB P06746 5/20 0.40
MAPT P10636 2/20 0.40
TDP1 Q9NUW8 2/20 0.40
QPCT Q16769 2/20 0.39
TERT O14746 1/20 0.38
CYP1A1 P04798 1/20 0.38
CYP1B1 Q16678 1/20 0.38
CHUK O15111 1/20 0.36
INSR P06213 1/20 0.36
MAPK8 P45983 1/20 0.36
CAMKK2 Q96RR4 1/20 0.36
MKNK1 Q9BUB5 1/20 0.36
MKNK2 Q9HBH9 1/20 0.36
KMT2A Q03164 2/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
KDM4E B2RXH2 3/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
ALDH1A1 P00352 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15210384 0.89 MAPK1 (0.43) ARCHUKINSRMAPK8CAMKK2
SCHEMBL15210587 0.89 AR (0.44) ARPOLBMAPTTDP1QPCT
SCHEMBL15210343 0.83 GAA (0.41) ARPOLBMAPTTDP1CYP1A1
SCHEMBL15210371 0.81 FLT1 (0.38) MAPTCHUKINSRMAPK8CAMKK2
SCHEMBL15210419 0.81 CAMKK2 (0.38) ARCHUKINSRMAPK8CAMKK2
SCHEMBL15210462 0.81 CAMKK2 (0.42) MAPTCHUKINSRMAPK8CAMKK2
SCHEMBL15210505 0.80 CAMKK2 (0.38) ARCHUKINSRMAPK8CAMKK2
SCHEMBL725317 0.80 FYN (0.45) CYP1A1CYP1B1CHUKINSRMAPK8
SCHEMBL15212570 0.80 MKNK1 (0.42) ARCYP1A1CYP1B1CHUKINSR
SCHEMBL15210392 0.80 KMT2A (0.42) POLBMAPTTDP1TERTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2817313-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2016-09-07 EP claimed
US-20150038527-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-02-05 US claimed
EP-2817313-A1 FUROPYRIDINE DERIVATIVES Merck Patent GmbH (DE) 2014-12-31 EP claimed
WO-2013124025-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2013-08-29 WO claimed
EP-2817313-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2016-09-07 EP disclosed
US-20150038527-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-02-05 US disclosed
EP-2817313-A1 FUROPYRIDINE DERIVATIVES Merck Patent GmbH (DE) 2014-12-31 EP disclosed
WO-2013124025-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2013-08-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038527-A1 FUROPYRIDINE DERIVATIVES SYK, LYN, BTK AR 2855/4885POLB 3229/4885MAPT 4864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.